Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

被引：6

作者：

Alidousty, Christina ^{[1
]}

Baar, Till ^{[2
]}

Heydt, Carina ^{[1
]}

Wagener-Ryczek, Svenja ^{[1
]}

Kron, Anna ^{[3
,4
,5
]}

Wolf, Juergen ^{[3
,4
,5
]}

Buettner, Reinhard ^{[1
,3
,4
]}

Schultheis, Anne Maria ^{[1
]}

机构：

[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[2] Univ Cologne, Fac Med, Inst Med Stat & Computat Biol, Cologne, Germany

[3] Network Genom Med, Cologne, Germany

[4] Univ Hosp Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, Cologne, Germany

[5] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

来源：

JOURNAL OF THORACIC DISEASE | 2019年 / 11卷

关键词：

Non-small cell lung cancer (NSCLC); anaplastic lymphoma kinase (ALK); ALK plus -adenocarcinoma; TP53; biomarker; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB RESISTANCE; PRACTICE GUIDELINES; TARGETED THERAPY; GROWTH-FACTOR; ALK; MUTATIONS; RECEPTOR; IDENTIFICATION; DIAGNOSIS;

D O I：

10.21037/jtd.2018.12.03

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase (ALK). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK+-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient's outcome.

引用

页码：S3 / S8

页数：6

共 50 条

[21] Deep learning in cancer pathology: a new generation of clinical biomarkers
Echle, Amelie
Rindtorff, Niklas Timon
Brinker, Titus Josef
Luedde, Tom
Pearson, Alexander Thomas
Kather, Jakob Nikolas
BRITISH JOURNAL OF CANCER, 2021, 124 (04) : 686 - 696
[22] Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada
Ionescu, D. N.
CURRENT ONCOLOGY, 2013, 20 (04) : 220 - 226
[23] Molecular pathology of lung cancer: current status and perspectives
Oberndorfer, Felicitas
Muellauer, Leonhard
CURRENT OPINION IN ONCOLOGY, 2018, 30 (02) : 69 - 76
[24] Practical Value of Molecular Pathology in Stage I–III Lung Cancer: Implications for the Clinical Surgeon
Christopher G. Azzoli
Annals of Surgical Oncology, 2015, 22 : 3459 - 3465
[25] Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?
Ilie, M.
Hofman, P.
CURRENT MEDICINAL CHEMISTRY, 2012, 19 (16) : 2638 - 2651
[26] Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice
Jiang, Wei-qin
Fu, Fang-fang
Li, Yang-xia
Wang, Wei-bin
Wang, Hao-hao
Jiang, Hai-ping
Teng, Li-song
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2012, 13 (09): : 663 - 675
[27] Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice
Wei-qin Jiang
Fang-fang Fu
Yang-xia Li
Wei-bin Wang
Hao-hao Wang
Hai-ping Jiang
Li-song Teng
Journal of Zhejiang University SCIENCE B, 2012, 13 : 663 - 675
[28] Molecular biomarkers of colorectal cancer:prognostic and predictive tools for clinical practice
Wei-qin JIANG1
Journal of Zhejiang University-Science B(Biomedicine & Biotechnology), 2012, (09) : 663 - 675
[29] A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma
Shoshan-Barmatz, Varda
Bishitz, Yael
Paul, Avijit
Krelin, Yakov
Nakdimon, Itay
Peled, Nir
Lavon, Avia
Rudoy-Zilberman, Elina
Refaely, Yael
ONCOTARGET, 2017, 8 (62) : 105492 - 105509
[30] Molecular Biology that Clinicians Should Know: From a Clinical Viewpoint
Adusumilli, P.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1639 - S1639

← 1 2 3 4 5 →